BAM
IMGN

Belpointe Asset Management’s Immunogen Inc IMGN Stock Holding History

Belpointe Asset Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-871
Closed -$3.35K – 3612
2023
Q1 		$3.35K Hold
871
– – ﹤0.01% 3160
2022
Q4 		$4.32K Buy
+871
New +$4.72K ﹤0.01% 2985

Other funds holding IMGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Belpointe Asset Management's IMGN Position: Q2 2023 in Review

Belpointe Asset Management sold out of Immunogen Inc (IMGN) in Q2 2023, closing a stake of 871 shares — an estimated $3.35K sold.

Belpointe Asset Management first reported a position in IMGN in Q4 2022 and held it in 2 quarters. The position peaked at $4.32K in Q4 2022. 266 funds tracked by Wall St. Rank hold IMGN as of Q2 2023.

  • Belpointe Asset Management reported no remaining Immunogen Inc position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 871 Immunogen Inc shares in Q2 2023, an estimated $3.35K.
  • Belpointe Asset Management first reported a position in Immunogen Inc in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Immunogen Inc position peaked at $4.32K in Q4 2022.
  • 266 funds tracked by Wall St. Rank held Immunogen Inc as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.